Oncolytics Biotech (TSE:ONC) Hits New 12-Month Low – Time to Sell?

Posted by Jessica Moore on Feb 3rd, 2025

Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) shares hit a new 52-week low during trading on Monday . The stock traded as low as C$0.98 and last traded at C$1.00, with a volume of 139671 shares. The stock had previously closed at C$1.07.

Wall Street Analyst Weigh In

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Read Our Latest Report on ONC

Oncolytics Biotech Stock Down 5.6 %

The company has a market cap of C$77.63 million, a price-to-earnings ratio of -2.66 and a beta of 1.35. The business has a 50-day simple moving average of C$1.24 and a two-hundred day simple moving average of C$1.37. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09.

Oncolytics Biotech (TSE:ONC – Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported C($0.12) earnings per share for the quarter, missing the consensus estimate of C($0.11) by C($0.01). During the same period in the previous year, the business posted ($0.14) earnings per share. As a group, equities analysts forecast that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.